Bolt Biotherapeutics, Inc. (BOLT) stock
BOLTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 11/3031% below fair value
$5.91−0.35 (-5.59%)
Close on Nov 12, 2026Market cap $11.38MP/E –Yield –
Bolt Biotherapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Bolt Biotherapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$29.84M. For fiscal 2025 it was -$34.82M. The highest annual figure on record is -$34.82M in fiscal 2025.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$34.82M | – |
| FY2024 | Dec 31, 2024 | -$71.27M | – |
| FY2023 | Dec 31, 2023 | -$74.34M | – |
| FY2022 | Dec 31, 2022 | -$88.66M | – |
| FY2021 | Dec 31, 2021 | -$91.60M | – |
| FY2020 | Dec 31, 2020 | -$48.57M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.20M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.40M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.83M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.41M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$11.72M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$16.00M | – |
| Q2 FY2024 | Jun 30, 2024 | -$22.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.63M | – |
| Q4 FY2023 | Dec 31, 2023 | -$19.30M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$19.37M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$20.58M | – |
| Q3 FY2022 | Sep 30, 2022 | -$21.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.65M | – |
| Q1 FY2022 | Mar 31, 2022 | -$23.52M | – |
| Q4 FY2021 | Dec 31, 2021 | -$26.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.22M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.51M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.15M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.70M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.23M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.64M | – |
See a number that looks wrong?